Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group

Katherine E. Warren, Tina Y. Poussaint, Gilbert Vezina, Darren Hargrave, Roger J. Packer, Stewart Goldman, Patrick Y. Wen, Ian F. Pollack, David Zurakowski, Larry E. Kun, Michael D. Prados, Stefan Rutkowski, Mark W. Kieran

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.

Original languageEnglish (US)
Pages (from-to)1397-1401
Number of pages5
JournalPediatric Blood and Cancer
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Antineoplastic Agents
Pediatrics
Clinical Trials
Drug Approval
Neoplasms
Magnetic Resonance Imaging
Pharmaceutical Preparations

Keywords

  • Brain
  • Imaging
  • Pediatric
  • RANO
  • Response
  • Tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Challenges with defining response to antitumor agents in pediatric neuro-oncology : A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. / Warren, Katherine E.; Poussaint, Tina Y.; Vezina, Gilbert; Hargrave, Darren; Packer, Roger J.; Goldman, Stewart; Wen, Patrick Y.; Pollack, Ian F.; Zurakowski, David; Kun, Larry E.; Prados, Michael D.; Rutkowski, Stefan; Kieran, Mark W.

In: Pediatric Blood and Cancer, Vol. 60, No. 9, 01.09.2013, p. 1397-1401.

Research output: Contribution to journalReview article

Warren, KE, Poussaint, TY, Vezina, G, Hargrave, D, Packer, RJ, Goldman, S, Wen, PY, Pollack, IF, Zurakowski, D, Kun, LE, Prados, MD, Rutkowski, S & Kieran, MW 2013, 'Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group', Pediatric Blood and Cancer, vol. 60, no. 9, pp. 1397-1401. https://doi.org/10.1002/pbc.24562
Warren, Katherine E. ; Poussaint, Tina Y. ; Vezina, Gilbert ; Hargrave, Darren ; Packer, Roger J. ; Goldman, Stewart ; Wen, Patrick Y. ; Pollack, Ian F. ; Zurakowski, David ; Kun, Larry E. ; Prados, Michael D. ; Rutkowski, Stefan ; Kieran, Mark W. / Challenges with defining response to antitumor agents in pediatric neuro-oncology : A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 9. pp. 1397-1401.
@article{230fe469e75e440daeabe08ae671151b,
title = "Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group",
abstract = "Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.",
keywords = "Brain, Imaging, Pediatric, RANO, Response, Tumor",
author = "Warren, {Katherine E.} and Poussaint, {Tina Y.} and Gilbert Vezina and Darren Hargrave and Packer, {Roger J.} and Stewart Goldman and Wen, {Patrick Y.} and Pollack, {Ian F.} and David Zurakowski and Kun, {Larry E.} and Prados, {Michael D.} and Stefan Rutkowski and Kieran, {Mark W.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1002/pbc.24562",
language = "English (US)",
volume = "60",
pages = "1397--1401",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Challenges with defining response to antitumor agents in pediatric neuro-oncology

T2 - A report from the response assessment in pediatric neuro-oncology (RAPNO) working group

AU - Warren, Katherine E.

AU - Poussaint, Tina Y.

AU - Vezina, Gilbert

AU - Hargrave, Darren

AU - Packer, Roger J.

AU - Goldman, Stewart

AU - Wen, Patrick Y.

AU - Pollack, Ian F.

AU - Zurakowski, David

AU - Kun, Larry E.

AU - Prados, Michael D.

AU - Rutkowski, Stefan

AU - Kieran, Mark W.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.

AB - Criteria for new drug approval include demonstration of efficacy. In neuro-oncology, this is determined radiographically utilizing tumor measurements on MRI scans. Limitations of this method have been identified where drug activity is not reflected in decreased tumor size. The RANO (Response Assessment in Neuro-Oncology) working group was established to address limitations in defining endpoints for clinical trials in adult neuro-oncology and to develop standardized response criteria. RAPNO was subsequently established to address unique issues in pediatric neuro-oncology. The aim of this paper is to delineate response criteria issues in pediatric clinical trials as a basis for subsequent recommendations.

KW - Brain

KW - Imaging

KW - Pediatric

KW - RANO

KW - Response

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84880360095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880360095&partnerID=8YFLogxK

U2 - 10.1002/pbc.24562

DO - 10.1002/pbc.24562

M3 - Review article

C2 - 23625747

AN - SCOPUS:84880360095

VL - 60

SP - 1397

EP - 1401

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 9

ER -